The burden of epilepsy and unmet need in people with focal seizures

Abstract

Background: Epilepsy is one of the most common neurological conditions worldwide.As a chronic condition, epilepsy imposes a significant burden on people with epilepsy and society. We aimed to assess the burden and unmet need of individuals with epilepsy and their caregivers, focusing on focal seizures, the main type of seizure in adults and children. Methods:A targeted evidence review of the burden of epilepsy, focusing on focal seizures, was conducted to identify articles reporting: epidemiology, mortality, morbidity, quality of life (QoL), and costs. Results:Focal seizures affect up to ∼61% of people with epilepsy. They are associated with an increased risk of injury and premature death than the general population. People with epilepsy also have high comorbidity, particularly depression, anxiety, and cognitive impairments. Higher seizure frequency, adverse treatment events, and employment concerns reduce QoL. A reduction in caregivers' QoL is also often reported. Epilepsy requires long-term treatment accounting for high individual costs.Hospitalizations and antiseizure medications (ASMs) are the leading cost drivers of inpatient management and indirect costs with high unemployment rates, particularly in drug-resistant populations. Despite the advent of new treatments, a high unmet need remains unaddressed; approximately 40% of people with epilepsy are drug-resistant, further increasing the risks associated with epilepsy. Conclusions:Our findings highlight a substantial burden of illness and unmet needs in individuals with focal seizures, especially those with drug-resistant epilepsy. Suboptimal treatment options negatively impact QoL and, consequently, a sizeable economic burden indicating the need for new treatments and prioritizing this conditionantiseizure medication, caregivers, costs, drug-resistant epilepsy, quality of lifeThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program

“…Patients with DRE may experience increased comorbidities, an increased risk of injuries, adverse events (AEs) from treatment and premature death. In addition, DRE may impact patients' employment status and quality of life 5,6 . While epilepsy is associated with a considerable economic burden, a country‐based study has suggested how modest improvements in seizure control could provide substantial economic benefits to society, 7 emphasizing the need for new ASMs that provide improved seizure control.…”

Association of Neighborhood Deprivation With Cognitive and Mood Outcomes in Adults With Pharmacoresistant Temporal Lobe Epilepsy

“…18,19,21,40 We hypothesize that brain morphology, as assessed using various neuroimaging techniques, may mediate the relationship between ADI and cognition in patients with epilepsy and have additional research underway to test this hypothesis. It should also be noted that epilepsy can place a significant burden on the patient and their support structure (e.g., medical expenses, adverse treatment events, employment concerns, and inability to drive), 41 potentially pushing them into areas with greater neighborhood deprivation. Furthermore, there is evidence to suggest that racialized inequalities in epilepsy result in greater burden among some racial/ethnic groups compared with non-Hispanic White individuals.…”

Lifestyle Behavioral Interventions and Health-Related Outcomes Among People with Epilepsy: A Review of Randomized Controlled Trials

“…Epilepsy currently affects 1.2% of the population, with ranging symptoms and quality of life (QOL) impairments, defined as an individual's perception of their well-being, such as not being able to drive, strobe light sensitivity, social stigma, or in some cases, needing a full-time caregiver. 1 There are multiple standards of care for treating epilepsy. While the primary approach involves prescribing medication, 30%-40% of people with epilepsy (PWE) are drug-resistant and must find alternative ways to cope.…”